ALLMedicine™ Hypercalcemia Center
Research & Reviews 1,819 results
https://clinicaltrials.gov/ct2/show/NCT04634552
Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...
https://clinicaltrials.gov/ct2/show/NCT00001345
Aug 12th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...
https://clinicaltrials.gov/ct2/show/NCT04108195
Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...
https://clinicaltrials.gov/ct2/show/NCT04933539
Aug 12th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...
https://doi.org/10.1016/bs.vh.2022.03.002
Vitamins and Hormones; Grunbaum A, Kremer R
Aug 12th, 2022 - PTHrP (parathyroid hormone related protein) is an important mediator of malignancy-related tumor progression and hypercalcemia that shares considerable homology and functionality with parathyroid hormone. In this chapter, we review what has been e...
Guidelines 4 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.
Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.
Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.
Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...
https://www.ncbi.nlm.nih.gov/books/NBK557876/
StatPearls Asif A, Farooq N.
Vitamin D is a fat-soluble vitamin that is found in some animal food products and is also synthesized in the human body via exposure to the sun. Toxicity of vitamin D leads to hypercalcemia and imbalance in the regulation of bone metabolism; the r...
Drugs 558 results see all →
Clinicaltrials.gov 157 results
https://clinicaltrials.gov/ct2/show/NCT04634552
Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...
https://clinicaltrials.gov/ct2/show/NCT04933539
Aug 12th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...
https://clinicaltrials.gov/ct2/show/NCT04108195
Aug 12th, 2022 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Overall rationale of study is that daratumumab in combination with talquetamab or t...
https://clinicaltrials.gov/ct2/show/NCT00001345
Aug 12th, 2022 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...
https://clinicaltrials.gov/ct2/show/NCT03839459
Aug 10th, 2022 - This is an open label, Phase II trial of denosumab 120mg subcutaneous (SC) for patients with smoldering multiple myeloma (SMM). Subjects will be recruited from the James P. Wilmot Cancer Center, University of Rochester in Rochester, New York. Pati...
News 245 results
https://www.mdedge.com/fedprac/avaho/article/256893/multiple-myeloma/agent-orange-exposure-transformation-mgus-multiple
Jyothi Dodlapati, MD, James A. Hall, DO et. al.
Aug 9th, 2022 - Multiple myeloma (MM) accounts for 1% to 2% of all cancers and slightly more than 17% of hematologic malignancies in the United States. 1 MM is characterized by the neoplastic proliferation of immunoglobulin (Ig)-producing plasma cells with ≥ 10% c.
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer
May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer
Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...
https://www.medscape.com/viewarticle/972299
Apr 18th, 2022 - Patients who receive parathyroidectomy for mild primary hyperparathyroidism show no benefits in survival or morbidity, including fractures, cancer, or cardiovascular outcomes over more than 10 years, when compared with those not receiving the surg...
https://www.medpagetoday.com/hematologyoncology/myeloma/96496
Jan 4th, 2022 - Multiple myeloma at a younger age did not portend more aggressive disease or worse outcomes but significantly shortened lifespan as compared with the general population without myeloma, according to one of the largest studies of its kind. Over a 1...